Decoding dynamic miRNA:ceRNA interactions unveils therapeutic insights and targets across predominant cancer

Selcen Ari Yuka1,2, Alper Yilmaz3

  • 1Department of Bioengineering, Yildiz Technical University, Istanbul, 34220, Turkey. selcenay@yildiz.edu.tr.

Biodata Mining
|April 16, 2024
PubMed

Insights

This study reveals tumor-specific competing RNA (ceRNA) interactions in lung, prostate, and breast cancers. A core network of 63 ceRNAs and 165 miRNAs was identified, offering potential targets for RNA-based cancer therapies.

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • Competing RNA (ceRNA) interactions are crucial for post-transcriptional regulation and depend on transcript abundance.
  • Existing studies on ceRNA cross-talk often overlook tissue-specific dynamics and the emergence/loss of ceRNAs in cancer.
  • Comprehensive analysis of tumor-specific ceRNA fluctuations compared to normal tissues is lacking.

Purpose of the Study:

  • To comprehensively analyze tumor-specific competing RNA (ceRNA) interactions in lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), and breast invasive carcinoma (BRCA).
  • To identify ceRNAs that are gained or lost in cancerous tissues compared to their normal counterparts.
  • To uncover a core network of ceRNAs and microRNAs (miRNAs) with potential as common therapeutic targets across these three cancer types.

Main Methods:

  • Comparative analysis of transcriptomic data from tumor tissues (LUAD, PRAD, BRCA) and corresponding healthy tissues.
  • Identification of tumor-specific ceRNA interactions by analyzing transcript abundance and cross-talk.
  • Construction of a core ceRNA-miRNA interaction network based on shared ceRNAs across the three cancer types.

Main Results:

  • Significant numbers of tumor-specific ceRNAs were identified in LUAD (3,204), PRAD (1,233), and BRCA (406), absent in normal tissues.
  • Ninety ceRNAs were found to be shared across all three cancer types, participating in tumor-specific interactions.
  • A core network comprising 63 ceRNAs and 165 miRNAs was identified, highlighting potential common therapeutic targets like GALNT7, KLF9, DAB2, and specific miRNAs (e.g., miR-106a/b-5p).

Conclusions:

  • Tumor-specific ceRNA interactions exhibit significant fluctuations compared to normal tissues.
  • A conserved core network of ceRNAs and miRNAs exists across LUAD, PRAD, and BRCA, suggesting common regulatory mechanisms.
  • This identified core network provides a foundation for developing novel RNA-targeted and RNA-mediated therapeutic strategies for these aggressive cancers.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K